Literature DB >> 29709195

Intracellular Drug Bioavailability: Effect of Neutral Lipids and Phospholipids.

Andrea Treyer1, André Mateus1, Jacek R Wiśniewski2, Hinnerk Boriss3, Pär Matsson1, Per Artursson1,4,5.   

Abstract

Intracellular unbound drug concentrations are the pharmacologically relevant concentrations for targets inside cells. Intracellular drug concentrations are determined by multiple processes, including the extent of drug binding to intracellular structures. The aim of this study was to evaluate the effect of neutral lipid (NL) and phospholipid (PL) levels on intracellular drug disposition. The NL and/or PL content of 3T3-L1 cells were enhanced, resulting in phenotypes (in terms of morphology and proteome) reminiscent of adipocytes (high NL and PL) or mild phospholipidosis (only high PL). Intracellular bioavailability ( Fic) was then determined for 23 drugs in these cellular models and in untreated wild-type cells. A higher PL content led to higher intracellular drug binding and a lower Fic. The induction of NL did not further increase drug binding but led to altered Fic due to increased lysosomal pH. Further, there was a good correlation between binding to beads coated with pure PL and intracellular drug binding. In conclusion, our results suggest that PL content is a major determinant of drug binding in cells and that PL beads may constitute a simple alternative to estimating this parameter. Further, the presence of massive amounts of intracellular NLs did not influence drug binding significantly.

Entities:  

Keywords:  3T3-L1; drug binding; intracellular drug bioavailability; lipid; membrane partitioning; phospholipid; proteomics; unbound concentration

Mesh:

Substances:

Year:  2018        PMID: 29709195     DOI: 10.1021/acs.molpharmaceut.8b00064

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

1.  Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations.

Authors:  Anne M Filppula; Rezvan Parvizi; André Mateus; Pawel Baranczewski; Per Artursson
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

2.  Impact of Intracellular Concentrations on Metabolic Drug-Drug Interaction Studies.

Authors:  Andrea Treyer; Mohammed Ullah; Neil Parrott; Birgit Molitor; Stephen Fowler; Per Artursson
Journal:  AAPS J       Date:  2019-06-18       Impact factor: 4.009

3.  A Cell-Free Approach Based on Phospholipid Characterization for Determination of the Cell Specific Unbound Drug Fraction (fu,cell).

Authors:  Andrea Treyer; Sandra Walday; Hinnerk Boriss; Pär Matsson; Per Artursson
Journal:  Pharm Res       Date:  2019-11-07       Impact factor: 4.200

4.  Predicting Volume of Distribution in Humans: Performance of In Silico Methods for a Large Set of Structurally Diverse Clinical Compounds.

Authors:  Neha Murad; Kishore K Pasikanti; Benjamin D Madej; Amanda Minnich; Juliet M McComas; Sabrinia Crouch; Joseph W Polli; Andrew D Weber
Journal:  Drug Metab Dispos       Date:  2020-11-25       Impact factor: 3.922

Review 5.  Advances in delivery methods of Arthrospira platensis (spirulina) for enhanced therapeutic outcomes.

Authors:  Omar Ashraf ElFar; Nashiru Billa; Hooi Ren Lim; Kit Wayne Chew; Wai Yan Cheah; Heli Siti Halimatul Munawaroh; Deepanraj Balakrishnan; Pau Loke Show
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

6.  Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations.

Authors:  Mohammed A A Saleh; Chi Fong Loo; Jeroen Elassaiss-Schaap; Elizabeth C M De Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-17       Impact factor: 2.745

7.  Nanotherapeutic Modulation of Human Neural Cells and Glioblastoma in Organoids and Monocultures.

Authors:  Issan Zhang; Paula Lépine; Chanshuai Han; María Lacalle-Aurioles; Carol X-Q Chen; Rainer Haag; Thomas M Durcan; Dusica Maysinger
Journal:  Cells       Date:  2020-11-07       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.